ValuEngine upgraded shares of Orchard Therapeutics (NASDAQ:ORTX) from a hold rating to a buy rating in a report published on Thursday, ValuEngine reports.
Separately, Zacks Investment Research cut shares of Orchard Therapeutics from a buy rating to a hold rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $23.80.
NASDAQ ORTX traded down $1.16 on Thursday, hitting $12.91. 228,325 shares of the stock were exchanged, compared to its average volume of 149,889. Orchard Therapeutics has a fifty-two week low of $8.65 and a fifty-two week high of $21.64. The firm has a market cap of $1.21 billion and a P/E ratio of -1.26. The firm has a 50-day simple moving average of $13.76.
Orchard Therapeutics (NASDAQ:ORTX) last posted its quarterly earnings results on Tuesday, May 28th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.14. On average, analysts predict that Orchard Therapeutics will post -1.57 earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Lindbrook Capital LLC acquired a new position in shares of Orchard Therapeutics in the 1st quarter valued at $53,000. Legacy Advisors LLC purchased a new stake in Orchard Therapeutics in the 1st quarter valued at $53,000. Exane Derivatives purchased a new stake in Orchard Therapeutics in the 2nd quarter valued at $60,000. Stanley Laman Group Ltd. purchased a new stake in Orchard Therapeutics in the 2nd quarter valued at $256,000. Finally, Jabodon PT Co. purchased a new stake in Orchard Therapeutics in the 1st quarter valued at $550,000. Institutional investors and hedge funds own 57.02% of the company’s stock.
Orchard Therapeutics Company Profile
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.
See Also: What are trading strategies for the 52-week high/low?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.